Cellular Biomedicine Group, Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $19.7300
- Today's High:
- $19.7500
- Open Price:
- $19.7400
- 52W Low:
- $11.48
- 52W High:
- $19.5
- Prev. Close:
- $19.7500
- Volume:
- 171977
Company Statistics
- Market Cap.:
- $0.357 billion
- Book Value:
- 1.675
- Revenue TTM:
- $0.000 billion
- Operating Margin TTM:
- -18526.51%
- Gross Profit TTM:
- $0.000 billion
- Gross Profit TTM:
- $0.000 billion
- Profit Margin:
- 0%
- Return on Assets TTM:
- -34.47%
- Return on Equity TTM:
- -93.51%
Company Profile
Cellular Biomedicine Group, Inc had its IPO on 2014-03-21 under the ticker symbol CBMG.
The company operates in the sector and industry. Cellular Biomedicine Group, Inc has a staff strength of 217 employees.
Stock update
Shares of Cellular Biomedicine Group, Inc opened at $19.74 at the start of the last trading session i.e. 2021-02-19.
The stocks traded within a range of $19.73 - $19.75, and closed at $19.75.
This is a 0% increase from the previous day's closing price.
A total volume of 171,977 shares were traded at the close of the day’s session.
In the last one week, shares of Cellular Biomedicine Group, Inc have slipped by -1.25%.
Cellular Biomedicine Group, Inc's Key Ratios
Cellular Biomedicine Group, Inc has a market cap of $0.357 billion, indicating a price to book ratio of 10.9433 and a price to sales ratio of 1217.8604.
In the last 12-months Cellular Biomedicine Group, Inc’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.036 billion. The EBITDA ratio measures Cellular Biomedicine Group, Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cellular Biomedicine Group, Inc’s operating margin was -18526.51% while its return on assets stood at -34.47% with a return of equity of -93.51%.
In Q2, Cellular Biomedicine Group, Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1031%.
Cellular Biomedicine Group, Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-2.776 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cellular Biomedicine Group, Inc’s profitability.
Cellular Biomedicine Group, Inc stock is trading at a EV to sales ratio of 1245.1361 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 1217.8604.
Cellular Biomedicine Group, Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
Cellular Biomedicine Group, Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
Cellular Biomedicine Group, Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
Cellular Biomedicine Group, Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, Cellular Biomedicine Group, Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, Cellular Biomedicine Group, Inc paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $19.75
- 52-Week High
- $19.5
- 52-Week Low
- $11.48
- Analyst Target Price
- $19
Cellular Biomedicine Group, Inc stock is currently trading at $19.75 per share. It touched a 52-week high of $19.5 and a 52-week low of $19.5. Analysts tracking the stock have a 12-month average target price of $19.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 3.56 indicating a short percent outstanding of 2%.
Around 3551.4% of the company’s stock are held by insiders while 2950% are held by institutions.
Frequently Asked Questions About Cellular Biomedicine Group, Inc
Similar Industry Stocks ()
Most Active
Top Gainers
Top Losers
About
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company’s CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.